Emicizumab
Adolescent
Kathelijn Fischermonoclonal_antibodyPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Adolescent cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Phentermine University of Colorado, Denver | Phase 2 | B |
Topamax University of Colorado, Denver | Phase 2 | B |
DACARBAZINE Children's Cancer Group, China | Phase 2/3 | CCC |
PREDNISONE TABLETS Children's Cancer Group, China | Phase 2/3 | CCC |
Inno-206 Children's Cancer Group, China | Phase 2/3 | CCC |
View all 18 →
Same molecule, other indications
Emicizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →